Open AccessEffectiveness and safety of cefpodoxime in upper respiratory tract infections in adult Egyptian population a report from the Egyptian STAR registry
Author(s) -
Osama Hamid,
Mohamed Abdel Aziz Abu Dokhan,
Ahmed Gamea,
Hesham Ali Ahmed,
Nabil Taha Feseekh,
Mohamed Attwa El Deghedy,
A. Abaza,
Medhat Fayez,
Mohamed Abdel Wahab,
Ahmed Ali Salem,
Mohsen Mahmoud,
Ahmed Monir Nassar,
Mohamed Ali El Sayed,
Magdy Beder,
Emad Ahmad El Assaly,
Mohamed El Henteely,
Mohamed El Okba,
Ossama Hegazy,
Mohamed El Tabakh,
Ali Seweedan,
Hussein El Zalat,
Yasser Ali El Sherbiny,
Ezzat Mostafa,
Akram Zaheer,
Osama Abdel Khalil,
Maher Bebawi,
Amir El Ogeilee,
Yasser El Naggar,
El Sayed Mahmoud,
Essam Farid,
Mohamed Alaa Farouk,
Essam Aouda,
Farouk Ahmed El Khouly,
Awad Ahmed El Makheih,
Mohamed Said Fathy Ashry,
Mohamed Yousry,
Magdi Hamza Mohamed,
Yasser Ahmed Mau,
M. Abd El- Nasser,
Mohamed Hussein Montasser,
Mohamed A. Hussein
Publication year - 2017
Publication title -
egyptian journal of ear nose throat and allied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 8
eISSN - 2090-3405
pISSN - 2090-0740
DOI - 10.1016/j.ejenta.2017.08.002
Subject(s) - cefpodoxime , medicine , tolerability , sinusitis , respiratory tract infections , adverse effect , upper respiratory tract infection , population , surgery , antibacterial agent , respiratory system , antibiotics , microbiology and biotechnology , biology , environmental health
Background: Cefpodoxime is a broad spectrum third generation cephalosporin with antibacterial activity similar to parenteral cephalosporins. Active against Gram-negative and -positive bacteria, empirical treatment with cefpodoxime is recommended for a wide range of community-acquired infections. We assessed the efficacy of cefpodoxime for the treatment of upper respiratory tract infections (URTI) in Egyptian adults, and evaluated its safety in daily practice. Methods: This prospective, observational, multicentre study recruited adult patients, presenting with acute maxillary sinusitis and tonsilopharyngitis, prescribed 200 mg/day cefpodoxime for 5â10 days by their physicians decision. Effectiveness, defined as the proportion of patients exhibiting a complete recovery of clinical symptoms for acute sinusitis and tonsilopharyngitis, was assessed. Safety was evaluated by measuring the prevalence and severity of adverse events (AEs). Results: A total of 1425 adult patients were recruited from 134 centers across Egypt. Significant reductions in URTI-related signs and symptoms were observed in subjects prescribed cefpodoxime for a mean 5.87 ± 1.73 days. An 83.3% cure rate and a 16.2% improvement rate were noted for both acute maxillary sinusitis and tonsilopharyngitis patients. Superior outcomes were observed in patients with acute tonsilopharyngitis compared to the acute maxillary sinusitis cohort (86.3% and 77.4%, respectively; p < 0.001). AEs were reported by 12 (0.8%) participants. All AEs were mild to moderate in intensity; none were serious and all were recovered. Conclusions: High cure rates for acute maxillary sinusitis and acute tonsilopharyngitis, and a favorable safety and tolerability profile were noted following treatment with cefpodoxime. Thus, cefpodoxime seems to be effective as empirical treatment in adult Egyptian patients with acute UTRIs. Keywords: Cefpodoxime, Cephalosporins, Upper respiratory tract infections, Acute maxillary sinusitis, Acute tonsilopharyngiti